|
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study.
|
28470677 |
2017 |
|
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
22142827 |
2012 |
|
Pancreatic carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
22142827 |
2012 |
|
Thrombocythemia, Essential
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
In the WHO 2008 criteria, pre-PMF was not defined as a subgroup of PMF; therefore, affected patients were at a higher risk of misdiagnosis with ET.
|
30977935 |
2019 |
|
Thrombocythemia, Essential
|
0.070 |
Biomarker
|
disease |
BEFREE |
Retrospective studies showed that survival of patients with pre-PMF is worse than that of ET and better than overt PMF.
|
30405096 |
2018 |
|
Thrombocythemia, Essential
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
There were 83 patients diagnosable only by the BCSH criteria (BCSH-only-ET), of which under the WHO classification, 69 patients fell under the category of MPN, unclassifiable (MPN-u), 12 patients were PMF, prefibrotic/early stage (pre-PMF), and 2 patients were polycythemia vera.
|
29405428 |
2018 |
|
Thrombocythemia, Essential
|
0.070 |
Biomarker
|
disease |
BEFREE |
In early-PMF compared to ET, the 10-year mortality rates (6.7% and 4.3%, P = .73), leukemic transformation rates (1.4% and 1.2%, P = .45), and thrombosis rates (16.7% and 12.2%, P = .12) were comparable.
|
28509339 |
2018 |
|
Thrombocythemia, Essential
|
0.070 |
Biomarker
|
disease |
BEFREE |
Furthermore, PT-INR was higher in ET and PMF mutated patients.
|
27976991 |
2017 |
|
Thrombocythemia, Essential
|
0.070 |
Biomarker
|
disease |
BEFREE |
Whole blood gene expression profiling was performed in 17 and 9 patients diagnosed with ET and PMF, respectively.
|
27579896 |
2016 |
|
Thrombocythemia, Essential
|
0.070 |
Biomarker
|
disease |
BEFREE |
Overall, 217 patients with ET (number 197) and early-PMF (number 20) were included in the analysis.Median follow-up time was 10.2 years.
|
25801912 |
2015 |
|
Primary Myelofibrosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate AURKA, BORA and PLK1 mRNA expression in unfractionated bone-marrow aspirates of 43 patients with myelofibrosis (28 primary-/PMF, 15 secondary-myelofibrosis/SMF) and 12 controls and to assess their clinical correlations.
|
31837568 |
2020 |
|
Primary Myelofibrosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Using these data, differentially expressed genes (DEGs) were identified between PMF and normal conditions using significance analysis of microarrays, and seed genes were determined based on the intersection of known pathogenic genes and the PMF gene expression profile.
|
29115418 |
2018 |
|
Primary Myelofibrosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
Retrospective studies showed that survival of patients with pre-PMF is worse than that of ET and better than overt PMF.
|
30405096 |
2018 |
|
Primary Myelofibrosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
In total, 199 patients with MPN (54 primary myelofibrosis [PMF], 79 essential thrombocythemia [ET], 58 polycythemia vera [PV], and eight MPN-unclassifiable [MPN-U]) and 4 patients with acute panmyelosis with myelofibrosis (APMF) were retrospectively subjected to Sanger sequencing for CALR, JAK2, and MPL.
|
25873496 |
2015 |
|
Primary Myelofibrosis
|
0.060 |
Biomarker
|
disease |
BEFREE |
We have identified a simple 5-gene signature, which is uniquely and highly significantly deregulated in patients in transitional stages of ET and PV towards myelofibrosis and in patients with PMF only.
|
24454890 |
2014 |
|
Primary Myelofibrosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Physicians treating patients with the classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF]) traditionally had few therapeutic drugs available.
|
21095048 |
2011 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Here, we discuss known and potential functions of tumor suppressor genes during tissue regeneration, focusing on the evolutionarily conserved tumor suppressors pRb1, p53, Pten and Hippo.
|
23715544 |
2013 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Additionally, we showed that the tumour suppressor pRb1 (retinoblastoma protein) is more sensitive to epigenetic-based anti-cancer stimuli than p53.
|
21635225 |
2011 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Several studies conducted so far have assessed the deregulation of the pRb1-pathway components in various human tumors and cell-lines, provided these pathway alterations play an obligatory role in tumorigenesis.
|
14670612 |
2004 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products.
|
9136893 |
1997 |
|
Myelofibrosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate AURKA, BORA and PLK1 mRNA expression in unfractionated bone-marrow aspirates of 43 patients with myelofibrosis (28 primary-/PMF, 15 secondary-myelofibrosis/SMF) and 12 controls and to assess their clinical correlations.
|
31837568 |
2020 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
This prospective cross-sectional study involves 36 MS patients (21 females, 15 males; age range 22-63 years; 15 relapsing-remitting MS - RRMS; 21 primary or secondary progressive MS - PMS) and 36 age-matched HC (20 females, 16 males); age range 21-61 years).
|
31176293 |
2019 |
|
Multiple Sclerosis
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
GBSI provided similar rates of atrophy, but reduced measurement variability compared to CSA in all MS subtypes (CIS: -0.95 ± 2.11% vs -1.19 ± 3.67%; RRMS: -1.74 ± 2.57% vs -1.74 ± 4.02%; PMS: -2.29 ± 2.40% vs -1.29 ± 3.20%) and healthy controls (0.02 ± 2.39% vs -0.56 ± 3.77%).
|
31385358 |
2019 |
|
Burning sensation
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
According to the positive matrix factorization (PMF) receptor model, primary sources for every four-year period were identified as oil burning, biomass burning, and vehicular emissions from gasoline and diesel-powered engines.
|
30716635 |
2019 |
|
Burning sensation
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
According to the source apportionment by diagnostic ratios and PMF model, coal combustion and traffic emission were estimated to be the main sources of PAHs in Dalian, followed by petroleum release and biomass burning.
|
30388687 |
2019 |